Repurposing an “old” drug for Multiple Myeloma Treatment
BY PAUL KLEUTGHEN Myeloma patients tend to have two interests in common : novel options…
Browsing: Multiple Myeloma News
Vitamin D Deficiency Before Transplant May Increase Myeloma Relapse Risk
Finding a vitamin D deficiency before an allogeneic (donor) stem cell transplant could mean an…
Donor Natural Killer Cell Therapy in Progress at University of Nebraska
Natural killer cells are yet another immunotherapy approach being developed in multiple myeloma. According to…
Bluebird Bio Aims to Lengthen and Deepen Responses with Second CAR T Cell Treatment
Bluebird bio has collaborated with Celgene Corporation on CAR T Cell treatments in multiple myeloma. …
Types and Aggressiveness of Myeloma Can Vary by Location in the Body Say UAMS Researchers
As seen on the UAMS Myeloma Institute website. Researchers with the Myeloma Institute at the University of…
Gene Discovery May Present a Future Option for Treating High Risk Multiple Myeloma
BY PAUL KLEUTGHEN It is becoming increasingly hard to keep up with the many advances…
New Drug Class from Cellectar Bioscience Shows Responses in Early Relapsed/Refractory Myeloma Studies
Cellectar Bioscience has run a series of early clinical trials using a new drug called…
The Relationship Between Myeloma Expertise and Clinical Outcomes
Does “geography” mean “destiny” when it comes to multiple myeloma? It turns out that being…
Utah Researchers Find that Fat Cells May Fuel Cancer
Article Referenced: Desert News Does obesity and fat cells have a connection to cancer growth?…
When Myeloma Patients Relapse After Becoming Refractory to Lenalidomide
BY PAUL KLEUTGHEN Several studies have been published recently that present the benefits of MM…
First Dual CAR T Cell Treatment on the Horizon for Multiple Myeloma
Many companies now have CAR T cell therapies in development for multiple myeloma. The most…
Genes That May Predict if Your Myeloma Responds to an Immunomodulator
In a recent retrospective study, top myeloma specialists collaborated to learn if any specific gene signature…
Second Blood Cancer Drug Approval in Two Days Confirms Treatment Theory
BY GREG BROZEIT The Food and Drug Administration (FDA) approved a “first drug of its…
Car T-Cell Research Moves Into Clinical Practice
The Food and Drug Administration (FDA) today approved “the first gene therapy available in the…
Stem Cell Transplant’s Impact on Relapsed Myeloma
When proteasome inhibitors (like bortezomib) and immunomodulators (like lenalidomide) were introduced in the early 2000s…
Blood Cancer Phase I NK Cell Clinical Trial Shows Durable Complete Responses
An immunotherapy called natural killer (NK) cells can be used with your own NK cells…
For newly diagnosed MM patients: the importance of lenalidomide maintenance therapy post Transplant
BY PAUL KLEUTGHEN The newly diagnosed MM patient will most likely be overwhelmed not only…
FDA Panel Recommends Approval for Novartis CAR T Cell Treatment in Leukemia
The Food and Drug Administration panel opened the door to widespread use of CAR T…
Second Study Shows Kyprolis® Improves Overall Survival for Relapsed/Refractory Myeloma
Final results from the Phase III ASPIRE study were published by Amgen showing that carfilzomib…
Patient Power: Progress in Immunotherapies and Precision Medicine
Dr. Hearn Jay Cho of Mount Sinai Hospital joined Andrew Schorr of Patient Power at…
MCRI Update: CAR T Cell Research, University of Würzburg
The Myeloma Crowd funded two key immunotherapy projects as part of the Myeloma Crowd Research…
EHA 2017: Elotuzumab Shows Long-Term Impact in 4-Year Study Follow-Up
Bristol-Myers Squibb presented four year updated data from their ELOQUENT-2 Trial, a trial enrolling 646…
FDA Places Keytruda Multiple Myeloma Studies on Hold
Merck & Co announced today that the FDA had placed a clinical hold on three…
EHA 2017: Newly Diagnosed Myeloma
Today many newly diagnosed myeloma patients will receive induction therapy and then go to stem…
EHA 2017: The Nature of Long Remissions
“I still haven’t found what I’m looking for.” U2 What makes one patient’s remission longer…
EHA 2017: The Art of Treating Multiple Myeloma
“The arrival of new effective drugs in such a short period of time is making…
EHA 2017: Myeloma Treatment for the Elderly or Transplant Ineligible
Myeloma therapy is getting better for elderly patients according to Graham Jackson, MD and Professor…
EHA 2017: Managing Myeloma Drug Side Effects
Today is the first day of the European Hematology Conference in Madrid, Spain. We will…
ASCO 2017: Three Studies for Newly Diagnosed Multiple Myeloma
Three studies were reported on at the recent ASCO 2017 conference that were specific to…
ASCO 2017: CAR T Cell Therapy Shows Incredible Results in Myeloma
At the recent ASCO 2017 conference, CAR T cell therapy demonstrated unprecedented results in several…
ASCO 2017: New Myeloma Bone Strengthener Shows Equal Benefit Compared to Zoledronic Acid
At the recent American Society of Clinical Oncology (ASCO) conference, Amgen presented data from a…
Artificial Virus May Become Foundation for Innovative Cancer Treatment
Swiss scientists from the University of Geneva (UNIGE), Switzerland, and the University of Basel have…
Keytruda, Pomalidomide and Dex Combination May Provide Impact for Relapsed/Refractory Myeloma Patients
The triple combination of pembrolizumab (Keytruda), pomalidomide and low dose dexamethasone was recently studied at the…
Minimal Residual Disease Negativity Becomes the New End Point in Myeloma Therapy
In a recent ASCO article by French myeloma specialists Jean-Luc Harousseau and Herve Avet-Loisea and…
Relapse of Multiple Myeloma: What Happens Next?
BY PAUL KLEUTGHEN This is a question that many of us ask ourselves after our…
Curcumin Gets Positive Results in Small MGUS and Smoldering Study
BY ERIC HANSEN Curcumin is beneficial to MGUS/SMM patients according to a small study published…
New Drug that Redirects Immune Cells Towards Myeloma Tumor Cells Cleared by FDA for Clinical Trial
The FDA has approved a new drug application by Glenmark Pharmaceuticals to begin a phase…
New Drug GMI-1271 May Help Velcade Work Again in Relapsed Myeloma
Velcade is an effective treatment for multiple myeloma, but some patients’ myeloma can become resistant…
Comparing Myeloma Minimal Residual Disease Tests: EuroFlow vs. New MSKCC Test
Evaluating myeloma patients after treatment with more sensitive testing to see how much disease is…
Myeloma 101: Vaccinations After Myeloma Stem Cell Transplant
BY PAUL KLEUTGHEN Should myeloma patients get re-vaccinated after stem cell transplant? Experts say there…
An Algorithm to Predict GvHD Post Allogeneic Stem Cell Transplants
BY PAUL KLEUTGHEN Some of us, myeloma patients as well as our caregivers and families,…
Sugar’s Smoke Screen and Cancer Cell Immunity
Researchers may have a sweet new way to help the immune system go after cancer…
Preventing Graft Vs. Host for Allogeneic (Donor) Stem Cell Transplant
City of Hope researchers led by Defu Zeng, professor of diabetes immunology and hematopoietic cell…
Novartis Shows Commitment to CAR T Cell Strategy
In August of last year, it was reported that Novaris was integrating its separate gene…
All you ever wanted to know about Immunomodulators (IMiDs) for Multiple Myeloma
BY PAUL KLEUTGHEN All of us are, most likely, familiar with products such as Thalomid,…
Progress in the Development of ‘Liquid Biopsies’ in Multiple Myeloma
BY PAUL KLEUTGHEN Several months ago the Broad Institute (a collaboration between MIT and the…
A New Bone Strengthener for Myeloma Patients
Multiple myeloma patients frequently have skeletal-related issues: spinal cord compression, fractures, surgeries and radiation to…
Halted Selinexor Clinical Trials Now Resume in Multiple Myeloma
On March 10, 2017, the FDA put a hold on all Selinexor clinical trials from…
Uncovering MGUS Mysteries: Should We Be Screening More for MGUS?
In the over 50 years of research since Dr. Robert Kyle, MD of the Mayo…
Aldevron Licenses Minicircle Technology for CAR T Cell Myeloma Treatments In Collaboration with the Myeloma Crowd
BY JAMES BROWN Aldevron to produce minicircles to support cell therapy applications Aldevron, along with…